Icon Plc (ICLR) to Post FY2018 Earnings of $5.87 Per Share, KeyCorp Forecasts

Icon Plc (NASDAQ:ICLR) – Investment analysts at KeyCorp cut their FY2018 earnings per share estimates for Icon in a research note issued on Tuesday, January 8th. KeyCorp analyst D. Hooker now expects that the medical research company will earn $5.87 per share for the year, down from their prior estimate of $6.07. KeyCorp also issued estimates for Icon’s Q4 2018 earnings at $1.60 EPS.

Icon (NASDAQ:ICLR) last released its earnings results on Wednesday, October 24th. The medical research company reported $1.54 EPS for the quarter, hitting analysts’ consensus estimates of $1.54. Icon had a return on equity of 26.08% and a net margin of 12.88%. The firm had revenue of $655.02 million for the quarter, compared to analysts’ expectations of $654.66 million.

ICLR has been the topic of a number of other reports. BidaskClub raised Icon from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 1st. Evercore ISI raised Icon from an “in-line” rating to an “outperform” rating in a research note on Friday, October 26th. Goldman Sachs Group cut Icon from a “conviction-buy” rating to a “buy” rating and set a $168.00 target price on the stock. in a research note on Friday, December 14th. Zacks Investment Research cut Icon from a “hold” rating to a “sell” rating in a research note on Tuesday. Finally, UBS Group started coverage on Icon in a research note on Tuesday, October 9th. They issued a “sell” rating and a $145.00 target price on the stock. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company’s stock. Icon presently has an average rating of “Buy” and an average target price of $150.00.

NASDAQ ICLR opened at $135.21 on Friday. Icon has a 12 month low of $101.22 and a 12 month high of $155.33. The firm has a market capitalization of $7.17 billion, a PE ratio of 22.46, a P/E/G ratio of 1.69 and a beta of 0.67. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.17 and a current ratio of 2.17.

Several institutional investors have recently added to or reduced their stakes in the stock. WCM Investment Management CA boosted its position in Icon by 7.9% in the third quarter. WCM Investment Management CA now owns 5,000,711 shares of the medical research company’s stock worth $768,860,000 after purchasing an additional 367,131 shares during the last quarter. Clearbridge Investments LLC boosted its position in Icon by 9.8% in the third quarter. Clearbridge Investments LLC now owns 2,211,986 shares of the medical research company’s stock worth $340,093,000 after purchasing an additional 198,271 shares during the last quarter. Partner Fund Management L.P. boosted its position in Icon by 61.1% in the second quarter. Partner Fund Management L.P. now owns 432,312 shares of the medical research company’s stock worth $57,294,000 after purchasing an additional 163,959 shares during the last quarter. Advisors Asset Management Inc. boosted its position in Icon by 3,097.7% in the second quarter. Advisors Asset Management Inc. now owns 153,202 shares of the medical research company’s stock worth $650,000 after purchasing an additional 148,411 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Icon by 77.0% in the third quarter. Bank of New York Mellon Corp now owns 291,956 shares of the medical research company’s stock worth $44,888,000 after purchasing an additional 127,009 shares during the last quarter. 86.42% of the stock is currently owned by institutional investors.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Article: Bull Market

Earnings History and Estimates for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply